You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

CLINICAL TRIALS PROFILE FOR TENOFOVIR ALAFENAMIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for tenofovir alafenamide

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00036634 ↗	A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients	Completed	Gilead Sciences	Phase 1/Phase 2	2002-03-01	This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
NCT01497899 ↗	Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Completed	Gilead Sciences	Phase 2	2011-12-28	The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗	D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults	Completed	Gilead Sciences	Phase 2	2012-04-01	This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for tenofovir alafenamide

Condition Name

Chart
Table

Condition Name for tenofovir alafenamide
Intervention	Trials
HIV Infections	34
HIV	28
HIV-1 Infection	24
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for tenofovir alafenamide
Intervention	Trials
Hepatitis B	54
HIV Infections	52
Hepatitis	48
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for tenofovir alafenamide

Trials by Country

Map
Table

Trials by Country for tenofovir alafenamide
Location	Trials
United States	827
Canada	99
China	82
France	66
Spain	50
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for tenofovir alafenamide
Location	Trials
California	61
Texas	52
Florida	51
Georgia	43
New York	41
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for tenofovir alafenamide

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for tenofovir alafenamide
Clinical Trial Phase	Trials
Phase 4	73
Phase 3	61
Phase 2/Phase 3	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for tenofovir alafenamide
Clinical Trial Phase	Trials
Completed	70
Recruiting	65
Not yet recruiting	33
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for tenofovir alafenamide

Sponsor Name

Chart
Table

Sponsor Name for tenofovir alafenamide
Sponsor	Trials
Gilead Sciences	84
National Institute of Allergy and Infectious Diseases (NIAID)	7
Janssen Research & Development, LLC	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for tenofovir alafenamide
Sponsor	Trials
Other	259
Industry	138
NIH	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.